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Ebola virus, for which we lack effective countermeasures, causes hemorrhagic fever in humans, with
significant case fatality rates. Lack of experimental humanmodels for Ebola hemorrhagic fever is ama-
jor obstacle that hinders the development of treatment strategies. Here, we model the Ebola hemor-
rhagic syndrome in a microvessel-on-a-chip system and demonstrate its applicability to drug studies.
Luminal infusion of Ebola virus-like particles leads to albumin leakage from the engineered vessels.
The process is mediated by the Rho/ROCK pathway and is associated with cytoskeleton remodeling.
Infusion of Ebola glycoprotein (GP1,2) generates a similar phenotype, indicating the key role of GP1,2 in
this process. Finally, wemeasured the potency of a recently developed experimental drug FX06 and a
novel drug candidate, melatonin, in phenotypic rescue. Our study confirms the effects of FX06 and
identifies melatonin as an effective, safe, inexpensive therapeutic option that is worth investigating
in animal models and human trials.1Division of Systems
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Ebola hemorrhagic fever is a rapidly progressive and highly fatal condition for which there is no established
treatment (Jameson et al., 2018). The Ebola epidemic in West Africa (2014–2016) was a health crisis of un-
precedented magnitude and impact, causing more than 11,000 deaths and destabilizing three countries
(Nicholas et al., 2016). Currently, World Health Organization and African countries are struggling to contain
a new large outbreak in Africa, which has led to hundreds of deaths (Dyer, 2019). Vascular integrity impair-
ment with subsequent blood volume loss (the so-called shock syndrome) is the primary cause of death in
patients with Ebola. Despite supportive care, more than 50% of patients die, with significant interindividual
differences in disease outcome reported and attributed to viral loads and host factors (de La Vega et al.,
2015; Hartley et al., 2017). Despite progress, many challenges remain to be addressed, including improving
early diagnosis, predicting disease progression, and developing therapeutic and preventive methods.
The lack of experimental models and sensitive detection tools has historically hindered the early detection
of Ebola vasculopathy and the development of Ebola drugs. However, rodent models that can mimic
certain aspects of Ebola disease in humans have been developed and are now used along with monkey
models as in vivo models of the disease (Bennett et al., 2017; de La Vega et al., 2018; Willyard, 2014).
The use of these models has recently led to the development of experimental therapeutic strategies,
including small molecules (Warren et al., 2016), antibodies (Olinger et al., 2012; Qiu et al., 2011, 2012; Wil-
son et al., 2000), and nanoparticles (Thi et al., 2015), as well as glycofullerenes (Munoz et al., 2016). However,
these therapeutics do not directly target hemorrhagic shock syndrome but rather Ebola virus infection.
Additionally, animal models are costly and cannot fully recapitulate the physiology and pathology of
human organs, making it difficult to predict the efficacy, safety, and toxicity of experimental Ebola drugs
(Mestas and Hughes, 2004).
In vitro human models for viral hemorrhagic shock syndrome are currently lacking. However, such models
would not only be useful for studying the pathogenesis of Ebola in a human-like setting but would also be
critical for diagnostics and drug development. Chip-based disease models are becoming important
research tools in biology and medicine (Reardon, 2015; Junaid et al., 2017; Tejavibulya and Sia, 2016).
Examples include the modeling of drug-toxicity-induced pulmonary edema in a lung-on-a-chip model
(Huh et al., 2012), the modeling of Alzheimer disease in a brain-on-a-chip platform (Park et al., 2015),
and the simulation of diabetic nephropathy in a glomerulus-on-a-chip microdevice (Wang et al., 2017).iScience 23, 100765, January 24, 2020 ª 2019 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Viral Hemorrhagic Syndrome-on-a-Chip
(A) Schematic diagram of the 96 microfluidic devices composing the gradient design (T-design) in the OrganoPlate, based on a 384 wells plate interface on
top and 96 microfluidic devices integrated in the bottom.
(B) Each microfluidic tissue chip consists of a microvessel compartment with medium inlet (1) and outlet (4), gel inlet (2), and observation window (3). The
dashed highlighted rectangular box indicates the region depicted in (C).
(C) Diagram of the monolayers of human umbilical vein endothelial cells (HUVECs) forming a microvessel next to the ECM in the microfluidic system.
(D) A 3D reconstruction showing the humanmicrovessel-on-a-chip that was formed by cultured HUVECs (red, F-actin) and demonstrated continuous on-chip
junctions (green, VE-cadherin). See also Video S1.
(E) Time-lapse fluorescence images of albumin (green) perfusion in the microvessel channel. Scale bar, 200 mm.
(F) 100 mMhistamine was pipetted in themedium inlet and outlet of the microfluidic device and incubated for 60min under perfusion with theMimetas rocker
platform. Subsequently, labeled albumin (green) was added to the medium inlet and outlet and time-lapse fluorescence images of albumin (green) diffusing
from the microvessel to the ECM channel were taken. Scale bar, 200 mm. See also Video S2 and S3.
(G) Apparent permeability (Papp) of microvessels in the time response to 100 mM histamine. The control is microvessel without histamine treatment.
Data are represented as mean G SEM.Additionally, there is a growing interest in using in vitro engineered models in vascular medicine (Jeon et
al., 2014; Kim et al., 2013, 2017; Qiu et al., 2018; van Duinen et al., 2017; Akbari et al., 2017; Bersini and Mor-
etti, 2015; Chen et al., 2017; Haase and Kamm, 2017; Hovell et al., 2015; Rayner and Zheng, 2016; Sato et al.,
2015; Shin et al., 2004; Smith andGerecht, 2014; Song et al., 2005; Takei et al., 2016; Tien, 2014), yet no chip-
based model of viral hemorrhagic shock syndrome has been introduced. Here, we develop, for the first
time, a microvessel-on-a-chip based model of Ebola (species Zaire ebolavirus) viral hemorrhagic syndrome
and demonstrate its usefulness by exploring the signaling and physical processes that underlie the hem-
orrhagic syndrome and by targeting those processes using drug candidates.
RESULTS
Here, we describe a simple chip-based model of Ebola-induced vascular integrity loss. To provide the
proof-of-principle for this approach and to ensure that the platform can be extended to a low-cost,
easy-to-use, high-throughput platform for diagnostics, we included the minimal components needed to
model the process. We first generated microvessels within the fabricated OrganoPlates (T-design) using
human endothelial cells (primary HUVECs) at the interface of a collagen type 1 network. The chip design
allowed us to culture 96 microvessels with heights of 120 mm and widths of 400 mm (see Figures 1A–1D
and Video S1). To develop the model and generate all the data for the current study, we have used approx-
imately a total of 550 independent chips. To ensure that the engineered vessel recapitulated the physio-
logical barrier function of a natural vessel, we measured the transport of albumin across the endothelial
wall into the collagen network. In a physiological setting, the vessel is expected to be impermeable but
to respond dynamically to physiological stimuli. Permeability experiments were carried out after incubating
the microvessels with and without histamine (an endogenous biogenic amine known to induce vascular2 iScience 23, 100765, January 24, 2020
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Figure 2. Microvascular Dysfunction in the Viral Hemorrhagic Shock Syndrome-on-a-Chip Platform
(A) Apparent permeability (Papp) of microvessels in response to Ebola VLPs at several time points. Microvessels were
exposed to 1 mg/mL VLPs, followed by a permeability assay.
(B) Concentration dependence of the VLP effect. Microvessels were treated for 2 h with the indicated concentrations of
VLPs, followed by a permeability assay.
(C) Endothelial cells stained for VE-cadherin (green) and F-actin (red) after exposure to 1 mg/mL VLPs for 2 h. A moderate
increase in actin filament stress fiber formation was observed (arrowheads). Pearson’s correlation coefficient was lower in
microvessels exposed to Ebola VLPs than in the control, showing an increase in stress fiber formation and endothelial cell
activation.
Data are represented as mean G SEM.permeability during inflammatory processes) for 40 or 60 min. As shown in Figure 1E, we observed no
leakage of albumin from the engineered vessels (control; without stimuli) within a 10-min interval during
the permeability assay (see Video S2). Permeability was, however, induced by the administration of hista-
mine, indicating that the endothelial wall is not passive and responds to stimuli as expected (see Figures
1E–1G and Video S3).
Next, we infused various concentrations of VLPs to determine whether VLPs alone are sufficient to induce
permeability and whether the extent of permeability is viral load dependent. Infusion of VLPs led to a dra-
matic increase in the permeability of the engineeredmicrovessels, as shown in Figures 2A and 2B. The VLPs
used in these experiments were non-replicating, indicating that the viral components interact directly with
endothelial cells and affect their barrier function, presumably by affecting cellular mechanics and intercel-
lular interactions. Immunostaining of F-actin indicated that Ebola VLPs indeed alter the mechanics and
physical interaction of endothelial cells, explaining the induction of permeability (see Figure 2C). However,iScience 23, 100765, January 24, 2020 3
treatment with VLPs did not result in an apparent rearrangement of VE-cadherin but instead caused a clear
increase in actin stress fiber formation, consistent with the findings in previous reports (Wahl-Jensen et al.,
2005). Moreover, we observed significant upregulation of E-selectin, a mediator of immune cell recruitment
and a biomarker for endothelial dysfunction, clearly indicating the activation of the engineered endothe-
lium (see Figure S1).
Next, we assessed whether VLPs affect cellular mechanics by modulating the Rho/ROCK pathway. Over-
activation of the Rho/ROCK pathway is an underlying mechanism of several vasculopathies, including
endotoxin-induced septic vasculopathy (Tasaka et al., 2005; Li et al., 2010; Suzuki et al., 2012). Given that
some of the major pathophysiological mechanisms of Ebola virus disease resemble those of bacterial sep-
tic shock (Mahanty and Bray, 2004; Bray and Mahanty, 2003), it is conceivable that the Rho/ROCK pathway
may also play a critical role in the pathogenesis of the severe vascular leak observed in Ebola disease (Eisa-
Beygi and Wen, 2015). To test this hypothesis, we first determined whether we could stimulate the Rho/
ROCK pathway in our engineered system and generate a phenotype similar to that observed after the infu-
sion of Ebola VLPs. We used U46619, a small molecule that activates the Rho/ROCK pathway andmeasured
the time- and concentration-dependent response of the vessels (Kobayashi et al., 2016). Treatment of the
microvessels with U46619 (10 mM) increased permeability significantly (see Figure 3A). As the concentration
of U46619 increased, the barrier permeability progressively increased (see Figure 3B). Immunostaining of
F-actin revealed induced alterations in the cellular cytoskeleton associated with the disruption of the
endothelial barrier (see Figure 3C). Subsequently, we investigated whether Rho/ROCK pathway inhibition
suppresses the Ebola-VLP-induced vascular phenotype. As RevitaCell Supplement (Hansen et al., 2018) is
known to specifically inhibit ROCK, we investigated whether this compound could reverse the Ebola-VLP-
induced phenotype. We compared vascular permeability of the microvessels-on-chips exposed to Ebola
VLPs only with permeability of microvessels exposed to Ebola VLPs and RevitaCell Supplement simulta-
neously to inhibit the Rho/ROCK pathway. We observed a full suppression of the VLP-induced permeability
upon administration of the inhibitor together with the VLPs (see Figure 4). This result shows that Ebola VLPs
critically modulate the Rho/ROCK pathway in hemorrhagic shock syndrome.
Existing evidence suggests that Ebola virus envelope glycoprotein GP1,2 is a key mediator of viral
pathogenesis and a determinant of disease severity (Mohan et al., 2015). To test whether GP1,2 alone could
simulate Ebola VLPs effect, we infused purified GP1,2 into our engineered vessels and measured the dose
and time responses. Figure 5A shows that stimulation with 100 ng/ml GPs1,2 for 120 and 240 min led to a
significant increase in vessel permeability. Moreover, we measured the dose-response curve using the
chip platform (see Figure 5B). Importantly, the increased permeability of GPs1,2-treated microvessels
was associated with the formation of stress fibers (see Figure 5C). These results directly show the ability
of Ebola GP1,2 to induce vasculopathy and indicate that our chip-based model can detect both VLP-
induced and GPs1,2-induced vascular permeability.
To demonstrate the applicability of our chip-based assay to pharmacological studies, we used this platform
to study the effect of two potential drugs. According to our simple working model, Ebola virus stimulates
the Rho/ROCK pathway, thereby inducing actin bundle formation and a tensile force that loosens the inter-
cellular junctions formed by VE-cadherin. We targeted this process at two levels: (1) Rho/ROCK signaling
(intracellular), via melatonin and (2) VE-cadherin (extracellular) and the associated actin bundles, via FX06
(see Figure 6A) (Bergt et al., 2016; Uyeki et al., 2016; Petzelbauer et al., 2005). We found that bothmolecules
effectively suppress vasculopathy and further showed that FX06, which binds to VE-cadherin, thus reducing
adhesion, also affects actin bundle formation directly (or indirectly via Fyn-mediated signaling (Groger
et al., 2009)) (Figure S2). Treatment with FX06 counteracted vascular leakage in VLP-treated vessels, which
is consistent with the results of previous animal experiments (Roesner et al., 2009) and the clinical benefit
noted in a case report (Wolf et al., 2015) (see Figure 6B). However, vascular integrity was not directly
measured in any previous study. Similarly, melatonin reduced vascular permeability in our viral hemorrhag-
ic shock syndrome-on-a-chip model (see Figures 6C and S3). A similar effect of melatonin was also
observed when we stimulated the Rho/ROCK pathway with U46619 (Figure S4). This observed effect of
melatonin is intriguing, as the effect of melatonin on the permeability of vessels has been previously re-
ported in the context of cancer and septic shock, and the function of melatonin has been attributed to
Rho/ROCK pathway modulation and subsequent changes to the cytoskeletal elements including actin
stress fibers (Borin et al., 2016; Tang et al., 2016). Melatonin has been proposed as a potential drug for
Ebola hemorrhagic shock (Masters et al., 2014; Tan et al., 2014; Wiwanitkit, 2014) but has never been tested4 iScience 23, 100765, January 24, 2020
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Figure 3. U46619 Induces Vascular Permeability in the Microvessel-on-a-Chip Platform
(A) Time dependence of U46619-induced barrier opening. Microvessels were exposed to 10 mM U46619, followed by a
permeability assay.
(B) Dose response to U46619 in microvessels. Microvessels were treated with several concentrations of U46619 for 1 h to
measure permeability.
(C) Immunofluorescence micrographs of on-chip cultured endothelium. After treatment for 1 h with 10 mM U46619,
endothelial cells were stained for VE-cadherin (green) and F-actin (red). An increase in actin stress fiber formation was
observed (arrowheads). Pearson’s correlation coefficient was lower in microvessels exposed to U46619 than in the control,
showing an increase in stress fiber formation and endothelial cell activation.
Data are represented as mean G SEM.experimentally. Given that melatonin is a natural molecule in the body and is safe when administered for at
least a year (Chahbouni et al., 2010) and given our observation that melatonin effectively suppresses the
Ebola-induced loss of vascular integrity, our study suggests that melatonin is a promising drug for treating
Ebola hemorrhagic shock syndrome. However, additional investigations are required to confirm the clinical
therapeutic efficacy of melatonin.
DISCUSSION
Vasculopathy is a critical and fatal consequence of Ebola virus infection (Bah et al., 2015; Escudero-Perez et
al., 2014; Lyon et al., 2014). Despite extended in vivo studies, the underlying molecular mechanisms are still
elusive, no effective cure is available, and treatment strategies are primarily palliative. To discover and
develop new drugs for Ebola in a cost-effective manner with high predictive power, microengineered dis-
ease models of human organs are needed. The hemorrhagic shock syndrome-on-a-chip described here isiScience 23, 100765, January 24, 2020 5
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Induced Vascular Permeability
Microvessels were either left untreated, incubated with 1 mg/mL Ebola
VLPs, or exposed to both RevitaCell Supplement (0.1 and 13) and
1 mg/mL Ebola VLPs simultaneously, with an incubation time of 2 h.
Data are represented as mean G SEM.the first of its kind. Despite its simplicity, this model is robust, with significant fidelity in mimicking, at least
partly, the structure and functions of human microvessels and Ebola disease-associated vasculopathy. This
platform permitted high-throughput simulation of the vascular permeability induced by Ebola VLPs and
Ebola GP1,2 as well as an increased surface expression of E-selectin, which mediates disseminated intravas-
cular coagulation and death (Boral et al., 2016; Tan et al., 2014).
Our study provides direct evidence for the usefulness of two candidate drugs, FX06 (which directly tar-
gets mechanical elements [Urbschat et al., 2014]) and melatonin (which directly targets biochemical
signaling [Yang et al., 2016]), for treating Ebola patients. Although melatonin and FX06 are not antiviral
molecules, they can be used to reduce the severity of hemorrhagic shock syndrome. Melatonin has not
been used clinically to treat Ebola before; however, it was used routinely in other several clinical settings
in humans (Sanchez-Barcelo et al., 2010). Intravenous administration of 60 mg melatonin (equivalent to
100 mM in blood) is believed to be safe and with no complications (Kucukakin et al., 2008; Gitto
et al., 2004). This indicates that the highest concentration of melatonin (100 mM) used in our study is
considered safe and can be translated to future clinical applications. Similarly, the highest concentration
of FX06 in our model is clinically relevant and has been used clinically to treat one Ebola patient (Wolf
et al., 2015).
Our in vitro model will help in understanding the underlying mechanisms of melatonin and FX06. This
will allow the development of new compounds capable of delaying the effect of Ebola-induced
vascular leakage. Additionally, the model can be of help in screening for therapeutic monoclonal anti-
bodies (Saphire et al., 2018a, 2018b), in which the effect of antibodies targeting endothelial cells or
VLPs to block the interaction between the two can be assayed. Finally, we stress the importance of
the dose-response analysis enabled by the proposed platform. Recently, some Ebola drugs such as
favipiravir have been abandoned because of problems with dosing (Dunning and Fischer, 2015). The
developed in vitro model can aid in the efforts to develop an effective pharmacokinetic model of
drug treatments and therefore, assist in designing the proper dose regimens. This chip-based platform
will thus be a valuable tool complementing state-of-the-art technologies for combating current and
future Ebola outbreaks.
Limitations of the Study
We note that this study has certain limitations that will be addressed in our future studies. The bidirection-
ality of the flow in the microvessels is one of the limitations in our system. Currently, we are developing a
perfusion pump, which can provide a unidirectional flow for each microvessel channel by covering the
whole plate, to solve this problem. We, however, anticipate that the observed vascular permeability re-
mains largely unaffected by the flow directionality, as our preliminary analysis shows (Figure S5). The6 iScience 23, 100765, January 24, 2020
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C
Figure 5. Endothelial Cell Activation Induced by the Ebola Glycoprotein
(A) Permeability assay of microvessels exposed to 100 ng/ml GP1,2 at the indicated time points.
(B) Dose response to GP1,2. Microvessels were incubated with GP1,2 at the indicated concentrations for 2 h to measure
permeability.
(C) Immunostaining of endothelial cells for VE-cadherin (green) and F-actin (red) after treatment with 100 ng/ml GP1,2. A
moderate increase in actin stress fiber formation was observed (arrowheads). Pearson’s correlation coefficient was lower
in microvessels exposed to Ebola GPs1,2 than in the control, showing an increase in stress fiber formation and endothelial
cell activation.
Data are represented as mean G SEM.proposed approach is high-throughput, yet the analysis time can be further reduced using high-content
imaging systems.
Our approach allows us to disentangle the direct contribution of VLPs and viral proteins to vascular
integrity loss from the contributions of host immunity (indirect mechanism) and the process of infection.
The proposed in vitro model can be used in future to address the contributions of immune cells and
to study endothelial cell infection. Shed glycoproteins from infected macrophages and dendritic cells
can be readily assayed using the proposed approach. The engineered vessels can be further improved
by including tissue specific ECM and other vascular cells (e.g., pericytes). The pharmacological analysis
can be further extended to investigate the kinetics of recovery (after titration of the inhibitors) in the
proposed in vitro model and to translate the results to nonhuman primate and human settings.
Certain control and complementary experiments need to be performed (e.g., testing VP40-only VLPs)
before exploring the translatability of the results. The platform can also be adapted to investigate ther-
apeutic antibodies and other drug options. Finally, this study will contribute to understandingiScience 23, 100765, January 24, 2020 7
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Figure 6. FX06 and Melatonin Effectively Ameliorate Vascular Integrity Loss in the Ebola Hemorrhagic Shock
Syndrome-on-a-Chip Model
(A) FX06 and melatonin rebalance mechanical forces in endothelial cells to restore vascular integrity in Ebola viral
hemorrhagic shock syndrome.
(B) Microvessels exposed to 1 mg/mL Ebola VLPs were treated with FX06 at the indicated concentrations for 2 h.
Subsequently, a permeability assay was carried out.
(C) Dose response to melatonin in microvessels exposed to 1 mg/mL Ebola VLPs for 2 h, followed by a permeability assay.
Data are represented as mean G SEM.and detection of other highly dangerous viral infections that cause hemorrhagic shock including Lassa
and dengue.METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.100765.ACKNOWLEDGMENTS
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Transparent Methods 
Chip design 
We designed a novel chip structure (T-design) based on the MIMETAS OrganoPlate platform. 
This new design involves a T-junction shown in Figure 1 in which the channels are separated 
by a phaseguide(Vulto et al., 2011). The design, due to its geometry, enables easy generation 
of leak tight vessels and quantification of vascular leakage. With the T-design there is a small 
area that has direct contact with the ECM, which makes it easy to create leak tight vessels 
compared to if a larger area of the microvessel has contact with the ECM. Additionally, this 
likely increases the duration of the permeability measurement before the system becomes 
saturated.  Fabrication of the glass chipsets was carried out by MIMETAS using a previously 
established protocol(Vulto et al., 2011).  
 
Cell culture 
Human umbilical vein endothelial cells (HUVECs) were cultured in Endothelial Cell Growth 
Medium 2 (C-39216; PromoCell). We used the T-design OrganoPlate for all microfluidic cell 
culture. Thus, the microvascular and extracellular matrix (ECM) channels were separated by 
phaseguides. Before seeding the cells, 4 mg/ml rat tail collagen type 1 (3440-005-01; 
Trevigen) neutralized with 10% 37 g/L Na2CO3 (S5761; Sigma) and 10% 1 M HEPES buffer 
(15630-056; Gibco) was added in the ECM channels. Subsequently, the collagen was let to 
polymerize by incubating the device for 10 min in the incubator at 37°C and 5% CO2. The 
observation windows were filled with 50 µl Hank’s Balanced Salt Solution with calcium and 
magnesium buffers (HBSS+; 24020117; Life Technologies) for optical clarity and to prevent 
gel dehydration. We trypsinized cells at 80-90% confluency and seeded 20·106 cells/ml in 
gelatin-coated microvascular channels of the OrganoPlate. Afterwards, the cells were 
incubated at 37°C and 5% CO2 for one hour to allow microvascular formation. After 
incubation, 50 µl of culture medium was added to the inlets and outlets of the microvascular 
channels. The device was placed on a rocker platform with a 7° angle of motion and an eight-
minute timed operation to allow continuous flow of medium in the microvessels. After 24 h, 
the medium was refreshed, and the HUVECs were cultured for an additional 3-4 days. 
 
Permeability assay 
Endothelial cell culture medium was spiked with U46619 (D8174; Sigma), Ebola virus-like 
particles (VLPs; ZEBO-VLP; The Native Antigen Company) and the Ebola virus envelope 
glycoprotein (GP1,2; EBOVKW95-ENV; The Native Antigen Company). The Ebola VLPs were 
diluted in 0.2% Endothelial Cell Growth Medium 2 to the desired experimental 
concentrations. RevitaCell™ Supplement (A2644501; ThermoFisher), FX06 (F4 Pharma GmbH) 
and melatonin (M5250; Sigma) were used to treat vessel permeability. To prevent the 
degradation of FX06 in the microvessels, 100 nM carboxypeptidase inhibitor (C0279; Sigma) 
was added. 
To measure vessel permeability, the ECM channel inlets were refreshed with 20 µl HBSS+. 
Then, the media in the inlets and outlets of the microvascular channels were replaced with 
40 µl and 30 µl, respectively, of 125 µg/ml Alexa Fluor 555-conjugated albumin (A34786; Life 
Technologies). Next, the OrganoPlate was placed in the environmental chamber (37°C; 5% 
CO2) of a fluorescence microscope system (Nikon Eclipse Ti), and time-lapse images were 
captured.  
We calculated the permeability coefficient by determining the fluorescence intensities in the 
microvascular (𝐼") and ECM (𝐼#) channels of the captured images and normalizing them to 
each other at each time point. This calculation showed the change in the intensity ratio inside 
the gel channel as a function of time. The area of the ECM channel (𝐴#) was 480 ∙ 10*+	𝑐𝑚/, 
and the length of the vessel wall between the ECM and microvascular regions (𝑙1) was 400 ∙10*2	𝑐𝑚. The scatter plot was fitted with a linear trend line to determine the slope, and the 
apparent permeability was calculated as follows: 
 
𝑃4""(∙ 10*+	𝑐𝑚/𝑠) = 𝑑 ;𝐼#𝐼"<𝑑𝑡 ∙ 𝐴#𝑙1  
 
 
Immunohistochemistry 
The medium was aspirated from the medium inlets, and the chip outlets and cells were fixed 
using 4% paraformaldehyde (PFA) in HBSS+ for 10 minutes at room temperature. The fixative 
was aspirated, and the cells were rinsed once with HBSS+. Next, the cells were permeabilized 
for two minutes with 0.2% Triton X-100 in HBSS+ and washed once with HBSS+. The cells were 
blocked in 5% BSA in HBSS+ for 30 minutes and incubated with the primary antibody solution 
overnight at 4°C. Mouse anti-human CD144 (1:100; 555661; BD Biosciences) and mouse anti-
human CD62E (25µg/ml; BBA26-200; R&D Systems) were used as the primary antibodies. The 
wells were washed with HBSS+, followed by a one-hour incubation with Hoechst (1:2000; 
H3569; Invitrogen), rhodamine phalloidin (1:200; P1951; SIGMA) and the secondary antibody 
solution, containing an Alexa Fluor 488-conjugated goat-anti-mouse antibody (1:250; R37120; 
Waltham). The wells were washed three times with HBSS+. High-quality Z-stack images of the 
stained cells were acquired using a high-content confocal microscope (Molecular Devices, 
ImageXpress Micro Confocal). Quantification of Pearsons’s correlation coefficient for the co-
localization of VE-cadherin and F-actin was performed using Coloc2 (ImageJ). Results are 
depicted as means ± SEMs (n=2). 
 
Statistical analysis 
We used IBM SPSS Statistics 23 for statistical analyses. Outliers in the box plots were identified 
by SPSS. The plotted data are the means ± SEMs of three or four biological replicates. Multiple 
comparisons were performed by one-way ANOVA followed by Dunnett’s t-test. The results 
were considered significant at *P < 0.05, **P < 0.01 and ***P < 0.001. 
Supplementary figures 
 
 
 
Supplementary figure 1 | Ebola VLPs elevated E-selectin in microvessels, Related to Figure 2. 
(a) Immunofluorescence for E-selectin expression (red) patterns in an untreated microvessel, 
1 µg/ml Ebola VLP-infected microvessels or 10 ng/ml TNF-a-treated microvessels for 18 h. (b) 
Quantitative determination of E-selectin expression in the absence (control) and presence of 
1 µg/ml Ebola VLPs or 100 ng/ml TNF-a for 2 h. Data are represented as mean ± SEM. A 
marginally significant difference (*P < 0.1) between the three conditions was found. 
 
 
 
 
 
 
 
Supplementary figure 2 | Endothelial cells stained for VE-cadherin (green) and F-actin (red) 
after exposure to 1 µg/ml VLPs with or without 100 ng/ml FX06 for 2 h, Related to Figure 6. A 
moderate increase in actin stress fiber formation was observed in microvessels exposed to 
Ebola VLPs (arrowheads). This increase was abrogated by FX06 treatment. Pearson’s 
correlation coefficient was used to quantify the co-localization of VE-cadherin and junction-
associated actin filaments. Data are represented as mean ± SEM. 
 
 
Supplementary figure 3 | Immunostaining of endothelial cells for VE-cadherin (green) and F-
actin (red) after exposure to 1 µg/ml of VLPs with or without 10 µM melatonin for 2 h, Related 
to Figure 6. A moderate increase in actin stress fiber formation was observed in microvessels 
incubated with Ebola VLPs (arrowheads). Treatment with melatonin reduced actin stress fiber 
formation. Pearson’s correlation coefficient was used to quantify the co-localization of VE-
cadherin and junction-associated actin filaments. Data are represented as mean ± SEM. 
 
 
 
 
 
 
 
 
Supplementary figure 4 | Melatonin reduced vascular permeability in U46619-treated 
microvessels, Related to Figure 6. (a) Microvessels exposed to 10 µM U46619 were treated 
with the indicated concentrations of melatonin for 1 h. Subsequently, a permeability assay 
was carried out. (b) Endothelial cells stained for VE-cadherin (green) and F-actin (red) after 
exposure to 10 µM U46619 with or without 10 µM melatonin for 1 h. A moderate increase in 
actin stress fiber formation was observed in microvessels incubated with U46619 
(arrowheads). This increase was abrogated by melatonin treatment. Pearson’s correlation 
coefficient was used to quantify the co-localization of VE-cadherin and junction-associated 
actin filaments. Data are represented as mean ± SEM. 
 
 
Supplementary figure 5 | U46619 induces leakage irrespective of the directionality of the flow 
within the microvessels, Related to Figure 3. The microvessels were incubated with 10 µM 
U46619 and perfused under unidirectional and bidirectional flow for 8 minutes, following a 
permeability assay. We did not observe a statistically significant difference between the two 
flow conditions. The data is generated using 42 chips, including 21 control chips and 21 
U46619 chips. Data are represented as mean ± SEM. 
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